Pablo Corral: The ANGPTL Axis in Dyslipidemia and Cardiovascular Risk
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Isabela C. Bitencourt et al., published in Current Atherosclerosis Reports, adding:
“The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies
The ANGPTL axis is rapidly becoming one of the most exciting frontiers in lipid therapeutics.
- ANGPTL3 inhibition lowers TG, remnants, LDL-C and apoB — importantly, through mechanisms largely independent of the LDL receptor.
- HoFH is already proof of concept: evinacumab reduced LDL-C by approximately 49%, irrespective of LDLR genotype.
- RNA therapeutics such as zodasiran and solbinsiran are expanding the field, providing sustained ANGPTL3 suppression and broad reductions in atherogenic lipoproteins.
- ANGPTL3/8 and ANGPTL4 are emerging as additional targets, particularly for TG- and remnant-rich dyslipidemia.
- And perhaps the most disruptive concept: one-time in vivo CRISPR-Cas9 editing of ANGPTL3, with early human data showing up to 80% ANGPTL3 suppression and sustained reductions in TG and LDL-C.
The key unanswered question: will these impressive lipid changes translate into fewer cardiovascular events?
The future of lipid lowering may not simply be about targeting another lipid, but about rewiring the pathways that control atherogenic lipoprotein metabolism.”
Title: The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies
Authors: Isabela C. Bitencourt, André Zimerman, Nicholas A. Marston
Other featuring Pablo Corral on Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH